Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities

Hoffy, Nada M. El; Azim, Engy A Abdel; Hathout, Rania M.; Fouly, Marwa A.; Elkheshen, Seham A.

doi:10.1016/j.ejps.2020.105648

Cited by 28 publications

(43 citation statements)

References 271 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They offer numerous advantages; for example, the surface of the nanocarrier can be modified using different polymers for different purposes, such as mucoadhesive properties, by increasing the residence time, thus tailoring the drug release to reach controlled or sustained delivery. Furthermore, enhanced bioavailability with a lower risk of adverse effects and eye irritation can be obtained to increase patients’ adherence to medications [ 28 , 91 , 92 , 93 , 94 , 95 ].…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

Omer

Zelkó

2021

Pharmaceutics

View full text Add to dashboard Cite

Currently, ocular inserts and nanoparticles have received much attention due to the limited bioavailability of conventional eye preparations and the toxicity problems of systemic drug administration. The current systematic review aims to present recent studies on the use of electrospun nanofiber-based ocular inserts to improve the bioavailability of drugs used for different ophthalmic diseases. A systematic search was performed in PubMed, Ovid Medline, Web of Science, ScienceDirect, Scopus, Reaxys, Google Scholar, and Google Patents/Espacenet taking “drug-loaded”, “nanofibers”, and “ophthalmic inserts” and their equivalent terms as keywords. The search was limited to original and peer-reviewed studies published in 2011–2021 in English language. Only 13 out of 795 articles and 15 out of 197 patents were included. All results revealed the success of nanofiber-based ocular inserts in targeting and improved bioavailability. Ocular inserts based on nanofibers can be used as safe, efficient carriers for the treatment of anterior and posterior eye diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

Omer

Zelkó

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…One such application is polymeric hydrogels, which are three-dimensionally organized molecular frameworks that enable drug molecules to be diffused throughout the entire structure, outfitting the hydrogel as a drug reservoir [ 101 ]. In addition to being transparent and highly biocompatible given their flexibility and high water content, polymeric hydrogels are generally well-adherent to the ocular surface leading to increased contact time and patient compliance by overcoming challenges associated with high dose frequency [ 102 , 103 ]. As biocompatible nanotechnology, polymeric vehicles can reduce both dosing regimen or adequate concentration by overcoming the lipophilic barrier of the corneal epithelium [ 104 ].…”

Section: Emerging Technologiesmentioning

confidence: 99%

Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications

et al. 2022

View full text Add to dashboard Cite

Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness. The disease has conventionally been characterized by an elevated intraocular pressure (IOP); however, recent research has built the consensus that glaucoma is not only dependent on IOP but rather represents a multifactorial optic neuropathy. Although many risk factors have been identified ranging from demographics to co-morbidities to ocular structural predispositions, IOP is currently the only modifiable risk factor, most often treated by topical IOP-lowering medications. However, topical hypotensive regimens are prone to non-adherence and are largely inefficient, leading to disease progression in spite of treatment. As a result, several companies are developing sustained release (SR) drug delivery systems as alternatives to topical delivery to potentially overcome these barriers. Currently, Bimatoprost SR (Durysta TM ) from Allergan plc is the only FDA-approved SR therapy for POAG. Other SR therapies under investigation include: bimatoprost ocular ring (Allergan) (ClinicalTrials.gov identifier: NCT01915940), iDose ® (Glaukos Corporation) (NCT03519386), ENV515 (Envisia Therapeutics) (NCT02371746), OTX-TP (Ocular Therapeutix) (NCT02914509), OTX-TIC (Ocular Therapeutix) (NCT04060144), and latanoprost free acid SR (PolyActiva) (NCT04060758). Additionally, a wide variety of technologies for SR therapeutics are under investigation including ocular surface drug delivery systems such as contact lenses and nanotechnology. While challenges remain for SR drug delivery technology in POAG management, this technology may shift treatment paradigms and dramatically improve outcomes.

show abstract

“…However, these technologies need further improvement, as new concerns have arisen regarding their use. The most important of which include ocular toxicity, the availability of proper in vivo models, and new sterilization techniques, as well as their physical stability [ 166 ].…”

Section: Future Development Direction Of Ocular Deliverymentioning

confidence: 99%

Recent Advances in the Excipients Used for Modified Ocular Drug Delivery

et al. 2021

View full text Add to dashboard Cite

In ocular drug delivery, maintaining an efficient concentration of the drug in the target area for a sufficient period of time is a challenging task. There is a pressing need for the development of effective strategies for drug delivery to the eye using recent advances in material sciences and novel approaches to drug delivery. This review summarizes the important aspects of ocular drug delivery and the factors affecting drug absorption in the eye including encapsulating excipients (chitosan, hyaluronic acid, poloxamer, PLGA, PVCL-PVA-PEG, cetalkonium chloride, and gelatin) for modified drug delivery.

show abstract

Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities

Cited by 28 publications

References 271 publications

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications

Recent Advances in the Excipients Used for Modified Ocular Drug Delivery

Contact Info

Product

Resources

About